tradingkey.logo

Tivic Health Systems Inc

TIVC
2.310USD
-0.060-2.53%
Cierre 11/04, 16:00ETCotizaciones retrasadas 15 min
2.23MCap. mercado
PérdidaP/E TTM

Tivic Health Systems Inc

2.310
-0.060-2.53%

Más Datos de Tivic Health Systems Inc Compañía

Tivic Health Systems, Inc. is a commercial health tech company advancing the field of bioelectronic medicine. The Company’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Its non-invasive and targeted approach to the treatment of inflammatory chronic health conditions is intended to give consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. The Company’s commercial product, ClearUP, is an FDA approved handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and available through online retailers and commercial distributors. ClearUP is sold in the United States directly to consumers on various platforms and through reseller channels. The Company is also focused on its intellectual property (IP) portfolio and research programs related to vagus nerve stimulation to expand its applications in non-invasive bioelectronic medicine.

Información de Tivic Health Systems Inc

Símbolo de cotizaciónTIVC
Nombre de la empresaTivic Health Systems Inc
Fecha de salida a bolsaNov 11, 2021
Director ejecutivoMs. Jennifer Ernst
Número de empleados7
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 11
Dirección47685 Lakeview Blvd
CiudadFREMONT
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94538
Teléfono18882766888
Sitio Webhttps://tivichealth.com/
Símbolo de cotizaciónTIVC
Fecha de salida a bolsaNov 11, 2021
Director ejecutivoMs. Jennifer Ernst

Ejecutivos de Tivic Health Systems Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
23.25K
+3192.78%
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--

Desglose de ingresos

Sin datos
Sin datos
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: jue., 2 de oct
Actualizado: jue., 2 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Statera BioPharma, Inc
3.89%
Avenue Venture Opportunities Fund LP
3.18%
Marex Group plc
2.50%
Ernst (Jennifer)
1.48%
UBS Financial Services, Inc.
0.36%
Otro
88.60%
Accionistas
Accionistas
Proporción
Statera BioPharma, Inc
3.89%
Avenue Venture Opportunities Fund LP
3.18%
Marex Group plc
2.50%
Ernst (Jennifer)
1.48%
UBS Financial Services, Inc.
0.36%
Otro
88.60%
Tipos de accionistas
Accionistas
Proporción
Corporation
7.07%
Investment Advisor
2.85%
Individual Investor
1.51%
Otro
88.56%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
2023Q3
33
160.42K
18.20%
+130.18K
2023Q2
33
60.32K
19.16%
+13.93K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Statera BioPharma, Inc
61.20K
3.89%
+61.20K
--
May 14, 2025
Avenue Venture Opportunities Fund LP
50.13K
3.18%
+50.13K
--
May 14, 2025
Marex Group plc
39.28K
2.5%
+39.28K
--
Jun 30, 2025
Ernst (Jennifer)
23.25K
1.48%
+22.54K
+3192.78%
Sep 22, 2025
UBS Financial Services, Inc.
5.65K
0.36%
+5.65K
--
Jun 30, 2025
Bambach (Kimberly Ann)
442.00
0.03%
--
--
May 14, 2025
Gurfein (Blake Ph.D.)
66.00
0%
--
--
May 14, 2025
SBI Securities Co., Ltd.
16.00
0%
--
--
Jun 30, 2025
BofA Global Research (US)
9.00
0%
+4.00
+80.00%
Jun 30, 2025
Susquehanna International Group, LLP
--
0%
-927.00
-100.00%
Dec 31, 2024
Ver más

ETFs relacionados

Nombre
Proporción
Sin datos

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Fecha
Tipo
Relación
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
KeyAI